Chinese consortium completes $605m buyout of Nasdaq-listed SciClone Pharma

Chinese consortium completes $605m buyout of Nasdaq-listed SciClone Pharma

Photo: Reuters

Nasdaq-listed SciClone Pharmaceuticals Inc. has been privatised and delisted from the New York-based stock exchange by a consortium consisting of entities affiliated with GL Capital Management GP Limited (GL Capital), Bank of China Group Investment Limited (BOCGI), CDH Investments, Ascendent Capital Partners and Boying.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter